Abstract Aims: To determine the effect of concomitant azathioprine treatment on the response of patients with renal failure to treatment with subcutaneous recombinant human erythropoietin (r-HuEPO). Methods: Two groups of patients with renal failure not receiving haemodialysis were studied. One comprised seven patients receiving erythropoietin alone, the second consisted of nine patients who were also treated with azathioprine. The haematological changes were monitored, and the functional erythropoietic response was studied by two different ferrokinetic models. One analysed the initial, the other the extended plasma iron clearance. Studies were performed
Abstract Aims: To determine the effect of concomitant azathioprine treatment on the response of patients with renal failure to treatment with subcutaneous recombinant human erythropoietin (r-HuEPO). Methods: Two groups of patients with renal failure not receiving haemodialysis were studied. One comprised seven patients receiving erythropoietin alone, the second consisted of nine patients who were also treated with azathioprine. The haematological changes were monitored, and the functional erythropoietic response was studied by two different ferrokinetic models. One analysed the initial, the other the extended plasma iron clearance. Studies were performed before r-HuEPO treatment on all 16 patients, and repeated on 11 of these when the target haemoglobin (10) (11) gIdl) was achieved and stabilised. Total erythropoiesis was determined using both techniques. Analysis of the extended plasma iron clearance also permitted calculation of both effective and ineffective erythroid activity. Results: The haematological response to r-HuEPO was the same for both patient groups. Measurement of total erythropoiesis by both ferrokinetic methods showed good correlation. For those receiving long term azathioprine, the percentage ineffective erythropoiesis was high compared with that of the other patients, and remained so for as long as they continued with azathioprine. For those uncomplicated by azathioprine treatment, r-HuEPO increased levels of both effective and ineffective erythropoiesis by the same degree. A substantial reduction in ineffective erythropoiesis was shown only by those patients who either discontinued or reduced their azathioprine once they started r-HuEPO treatment.
Conclusions: Azathioprine increases ineffective erythropoiesis. In this study, the r-HuEPO dose was sufficient to overcome this effect and promoted effective erythropoiesis so that the anaemia lessened. Measurement of total erythropoiesis provided limited information on the functional changes involved, differentiation of effective from ineffective erythropoiesis being necessary to define the changes after azathoprine reduction or withdrawal. Ineffective iron turnover (lIT)
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Percentage ineffective iron turnover (IIT%) 13-34% observed in those taking azathioprine following a change in the azathioprine dose for four patients. Azathioprine was withdrawn from cases 12 and 15. Case 12 was originally receiving 150 mg daily and case 15 50 mg daily. Both doses were withdrawn at six and three months, respectively, before the posttreatment ferrokinetic study was started. Cases 10 and 11 both had their azathioprine dose reduced one month before the post-treatment studies, case 11 from 100 mg to 75 mg daily, and case 10 from 150 mg to 100 mg. These changes resulted in a substantial reduction in ineffective erythropoiesis in all four patients. A close correlation between the ETU and MIT was recorded for all patients (figure). An increase in red cell survival (RCS) was recorded for two patients only (cases 4 and 12). for treatment of both pre-dialysis and CAPD patients. Stimulation of erythropoiesis resulted in rapid mobilisation of iron stores, reflected by a sharp fall in serum ferritin concentration. All patients reported improvements in their sense of wellbeing, appetite, and activity levels. The benefits of treatment with subcutaneous r-HuEPo have also been documented in several previous publications.24 .26 Ferrokinetic studies showed that, within the time span of our study, expansion of the erythron by r-HuEPO, rather than an alteration in red cell survival, was primarily responsible for the initial improvement in the anaemia of both patient groups. Nevertheless, previous work has indicated that significant improvements in red cell survival may occur after nine to 15 months of treatment, the explanation for this later improvement remaining unclear. 13 Total erythroid activity was expressed either as erythron transferrin uptake (ETU) 6 or marrow iron turnover (MIT). " The close correlation observed between the ETU and MIT for the renal patients has also been reported for cases of myelofibrosis and myelodysplasia. 27 The advantage of ETU measurements resides in the fact that a one day study period only is required, rather than the 10 to 14 days necessary for MIT measurements. The latter method, however, has the advantage of differentiating effective from ineffective erythropoiesis.
For patients to whom azathioprine was not given, r-HuEPO produced an increase in both effective and ineffective erythropoiesis, the ratio of these two components remaining unaltered. Thus for these patients the resultant changes in erythroid activity were adequately defined by measurements of total erythropoiesis, expressed as either the MIT or ETU.
However, in patients receiving azathioprine these parameters did not provide a complete explanation of the functional changes accompanying r-HuEPo treatment. Azathoprine is metabolised to a purine antagonist which interferes directly with erythroid activity, producing the high level of ineffective erythropoiesis recorded for patients receiving this drug. This increase persisted for as long as the patients took azathoprine. Nevertheless, this group still derived benefit from treatment with r-HuEPO. The erythropoietin dose administered in this study seemed to be sufficient to overcome the inhibitory effect of azathioprine on erythroid activity, and promoted effective erythropoiesis to the level required for an improvement in anaemic state. A substantial reduction in ineffective erythropoiesis was shown only by those patients who either discontinued or reduced their azathioprine dose once they started r-HuEPO treatment. In such cases measurement of changes in total erythropoiesis provided only limited information on the functional erythropoietic activity. This was particularly evident when the increase in effective erythropoiesis was accompanied by a substantial decrease in ineffective erythropoiesis. As total erythropoiesis is the summation of effective and ineffective erythropoiesis, the resultant changes recorded for total erythroid activity in such cases may not accurately reflect the improvement indicated by the increase in red cell volume.
Ferrokinetic studies provide an insight into the functional changes following r-HuEPO treatment. However, to obviate any misinterpretation of data, stringent attention must always be paid to the effect of additional treatment which may itself influence erythroid activity.
